<DOC>
	<DOCNO>NCT00591565</DOCNO>
	<brief_summary>This study design evaluate anxious patient partially responsive typical SSRI SNRI anti-anxiety medication therapy . Patients less 50 % anxiety-alleviated SSRI medication ask join study place Acamprosate well . This type add-on therapy common outpatient psychiatric care . This rater-blinded , patient open-label , non-placebo prospective study , subject receive Acamprosate 8 week . This study would first date treatment-resistant patient population , investigator utilize comprehensive set rating scale order best categorize patient response regard anxiety , co-occurring depression , sleep disorder , alcohol use , social function drug . This study may pivotal initiation future double-blind , placebo-controlled study agent</brief_summary>
	<brief_title>An 8 Week Open-Label Study Evaluate Efficacy Safety Acamprosate Calcium ( Campral ) Augmentation Therapy Patients With Anxiety Symptoms Who Are Only Partial Responders SSRI SNRI Antidepressants</brief_title>
	<detailed_description>Acamprosate felt restore normal glutamate-GABA balance human brain . ( Glutamate stimulate chemical brain , GABA inhibitory chemical brain . ) This GABA-glutamate balance felt play role development anxiety . Low GABA high glutamate level ( similar state alcohol withdrawal ) implicate . Symptoms anxiety may include worry , sweat , nausea , palpitation , tremor , comparable alcohol withdrawal . Sometimes , GABA-promoting sedative drug , diazepam ( Valium ) use raise GABA activity ward anxiety symptom non-alcoholic patient . GABA sedatives also use treat alcohol withdrawal restore balance short term . Given similar glutamate-GABA imbalance anxiety state ( post ) -alcohol withdrawal state , Acamprosate may likely candidate treat anxiety . Acamprosate FDA approve prolong sobriety decrease alcohol consumption . The usual initial treatment anxiety use serotonin neurotransmitter enhance drug , fluoxetine ( Prozac ) . These 'SSRI ' drug , unlike sedative note , addiction potential safer use . In addition serotonin-norepinephrine facilitating drug also use ( SNRIs ) alternative . In anxiety disorder population , 30-70 % patient achieve full relief anxiety symptom place SSRI monotherapy . The usual second-line choice promote full anxiety symptom remission add GABA-sedative serotonergic SSRI . The author feel Acamprosate , give ability manipulate GABA-glutamate balance without major side effect , addiction , may reasonable add-on augmentation strategy well alleviate anxiety SSRI partial responder . This study design evaluate anxious patient partially responsive typical SSRI SNRI anti-anxiety medication therapy . Patients less 50 % anxiety-alleviated SSRI medication ask join study place Acamprosate well . This type add-on therapy common outpatient psychiatric care . This rater-blinded , patient open-label , non-placebo prospective study , subject receive Acamprosate 8 week . This study would first date treatment-resistant patient population , investigator utilize comprehensive set rating scale order best categorize patient response regard anxiety , co-occurring depression , sleep disorder , alcohol use , social function drug . This study may pivotal initiation future double-blind , placebo-controlled study agent</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<mesh_term>Serotonin Noradrenaline Reuptake Inhibitors</mesh_term>
	<criteria>1 . Written inform consent obtain . 2 . The patient Englishspeaking 18 64 year age inclusive . 3 . The patient meet DSMIV criterion anxiety disorder determine MINI psychiatric evaluation . These include : PostTraumatic Stress Disorder ( PTSD ) , General Anxiety Disorder ( GAD ) , Social Anxiety , Panic Disorder . 4 . The patient currently take monotherapy SSRI ≥ 6 week stable , adequate therapeutic ≥ 4 week remain anxiety symptomatic 5 . The patient total score least 16 HAMA scale 6 . The patient score least 7 HADS anxiety subscale score screen baseline visit . 7 . The patient CGIS rating 4 high screening 8 . The patient good health determine medical psychiatric history , medical examination , major medical illness would jeopardize patient health study . 9 . Women must nonchildbearing potential [ i.e. , postmenopausal , surgically sterile ( hysterectomy tubal ligation ) ] must meet following condition : use reliable , medically accept form contraception least 60 day baseline visit , agree continue use throughout duration study 30 day final dose study drug . Reliable form contraception include oral , implanted , injected contraceptive ; intrauterine device place least 3 month ; adequate barrier method conjunction spermicide ( abstinence consider acceptable contraceptive regimen ) . Women must give pregnancy test ( ßHCG ) , unless least 2 year postmenopausal surgically sterile , result test must negative . 10 . The patient must willing able comply study restriction remain clinic require duration study period , willing return clinic followup evaluation specify protocol . Patients exclude participate study 1 follow criterion meet : 1 . The patient one antidepressant take stand sedative anxiolytic 2 . The patient substance misuse disorder ( include alcohol , caffeine , nicotine ) 3 . The patient significant risk suicide 4 . The patient recently start psychotherapy counseling ( within last 6 week ) 5 . The patient psychiatric AxisI disorder principal diagnosis ( except anxiety ) within 6 month screen baseline visit ; history OCD , psychotic disorder , bipolar disorder , eat disorder , mental retardation , clear personality disorder . Patient may comorbid substance misuse , depressive anxiety disorder remission least 6 month prior screen visit . 6 . The patient previously participate clinical study acamprosate treat acamprosate . 7 . The patient use investigational drug within 1 month screen visit participate concurrent clinical trial . 8 . The patient disorder may interfere drug absorption , distribution , metabolism , excretion ( include gastrointestinal surgery ) . 9 . The patient unlikely comply study protocol , unreliable provide rating , unsuitable reason , judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Anxiety</keyword>
	<keyword>SSRI</keyword>
	<keyword>SNRI</keyword>
	<keyword>Acamprosate</keyword>
</DOC>